Free Newsletter
Vasella debates animal-rights extremists
Unlike other victims of animal rights extremists, Daniel Vasella isn't lying low, the Financial Times reports. Instead, he's personally warned 140 people who sent him critical emails "willingly or not you are associating yourself with criminal activity." And he defends his and his company's pharmaceutical testing, saying that those who try to prevent medical research should be "ashamed."
The warning and scolding comes via a letter seen by the FT, sent to people who had emailed the Novartis CEO about the company's animal research activities. Vasella and Novartis (NVS) have been targeted by animal rights activists, who not only desecrated the graves of Vasella's family members, but planned personal attacks on company employees.
Animal rights extremists have targeted drug company executives before. Most of them, however, don't personally fight back, the FT points out. Vasella has been different. He went on television soon after the most recent attacks--which included arson on his hunting lodge in the Tyrol--and now has personally argued with those who sent email. "We strongly condemn the use of violence and terrorist tactics... as a substitute for meaningful, productive dialogue," his letter stated. Will the emailers offer dialogue instead? We'll have to wait and see.
- read the FT piece
Related Articles:
Vasella calls activist attacks 'terrorism'
Militants target drug execs in wide range of attacks
'Militant' group claims Novartis attack
Extremists accused in attacks on Novartis chief
Activists torch Novartis CEO's home, steal mother's ashes
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: